Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Gene therapy trial in peripheral vascular disease

Early indications are that gene therapy can help in the treatment of patients with peripheral vascular disease, said Professor Seppo Ylä-Herttuala (University of Kuopio, Finland).

He reported interim results from a trial involving patients with severe lower limb ischaemia who were given arterial gene therapy during angioplasty.

The trial included 27 patients: nine in a control group (angioplasty only) and 18 who received therapy with the gene for vascular endothelial growth factor (VEGF), delivered either via liposomes or adenoviruses. Treadmill tests to assess improvement had not yet been carried out. However, angiographic studies had shown definite increased vascularity in the treated legs.

Professor Ylä-Herttuala said that it was unclear whether the improved vascularity resulted from production of new blood vessels or improved flow through previously blocked vessels. As well as inducing new vessels (angiogenesis), VEGF was vasculoprotective. It stimulated endothelial production of nitric oxide and prostacyclin, which had vasodilator and antiplatelet properties. The process of opening up an atherosclerotic artery by angioplasty could itself damage the endothelium (the inner lining of the blood vessel), and this, in turn, frequently led to restenosis and thrombosis. VEGF might stimulate endothelial repair and prevent platelet aggregation.

In the trial, benefit was maintained at three-month follow up, although the gene would only be expected to be expressed for two to three weeks. Professor Ylä-Herttuala suggested that VEGF helped with the initial re-establishing of blood flow and then “nature keeps the vessel open.” If this type of treatment turned out to be successful, repeat gene therapy might be needed every six months or so. He emphasised that the gene therapy only had a local effect, so minimising any concern over stimulation of angiogenesis in tumours.

VEGF could not be injected directly because it was cleared very rapidly (within two minutes). The gene therapy appeared to be safe, although some patients receiving the adenoviral vector (which was more effective than liposome transfer) had fever and slight increases in liver enzymes. Professor Ylä-Herttuala emphasised that randomised trials, with controls, were essential in gene therapy. Trials had not always been carried out properly and this had led to the recent negative publicity about this type of therapy.

Citation: The Pharmaceutical Journal URI: 20002124

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Pathology and Therapeutics for Pharmacists

    Pathology and Therapeutics for Pharmacists

    An practical, integrated approach to the pathophysiological and pharmacotherapeutic principles underlying the treatment of disease.

    £54.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Biological Therapeutics

    Biological Therapeutics

    An introduction to the treatment of disease using biological medicines derived from living plant and animal tissues.

    £33.00Buy now
  • Basic Pharmacokinetics

    Basic Pharmacokinetics

    A clear and concise basic pharmacokinetics textbook. Shows how to apply the principles to achieve successful drug therapy.

    £54.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Rate
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.